ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2609

Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0

Jessica Meijs1, Daisy Pors1, Theodora P.M. Vliet Vlieland2, Tom W.J. Huizinga1 and Annemie J.M. Schuerwegh1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Health Care, Questionnaires, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of life. To identify and evaluate GIT involvement in patients with SSc, the University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) was developed. The UCLA GIT 2.0 consists of 34 items on 7-multi-item subscales. The total score averages 6 of 7 scales (excluding constipation) and ranges from 0 (no GIT problems) to 3 (most severe GIT problems) [1]. The aim of our study was to translate the UCLA GIT 2.0 from English into Dutch and validate the Dutch version.

Methods: First, the UCLA-GIT 2.0 questionnaire was translated according to international guidelines [2]. Secondly, the questionnaire was field-tested among 17 SSc patients. Then, in order to test internal consistency and validity, the final Dutch version was administered to SSc patients participating in a standardized, annual comprehensive medical assessment, compromising visits to health care professionals, laboratory and cardiopulmonary investigations, the SSc Health Assessment Questionnaire (SHAQ) and Short Form-36 (SF-36). The internal consistency was tested by computing Cronbach’s alpha. For convergent and construct validity, Pearson correlations were computed between the Dutch UCLA-GIT and the SF-36 and SHAQ. (r≤ 0.29 is considered a small correlation, r 0.30 -0.49 a moderate, and r ≥ 0.50 a strong correlation). To determine the reliability, the instrument was re-administered with an interval of two weeks to 27 of the patients, and the intraclass-correlation coefficient (ICC) was computed.

Results: Ninety-two patients were included. Patients were on average 53.8 (SD 15) years, mostly women (76%), Caucasian (82%) and 53% of the patients had limited cutaneous SSc. The median total UCLA GIT 2.0 score was 0.18 and a floor effect was seen (17% scored 0). Cronbach’s alpha was ≥0.73 for all scales, except diarrhea (alpha=0.42). The total GIT score was weakly or moderately associated with the SF-36 mental component summary scale (r=-0.247, p<0.05), the SF-36 physical component summary scale (r=‑0.348, p<0.01) and the SHAQ score (r=0.287, p<0.01). Correlations between the GIT subscale scores and the SF-36 subscale scores were strong with respect to the corresponding emotional wellbeing and social functioning scale (r=-0.515, p<0.01). The test-retest reliability was acceptable (ICC: 0.788).

Conclusion: The Dutch UCLA GIT 2.0 questionnaire showed good internal consistency, reliability and an acceptable construct validity according to comparisons with SF-36 and SHAQ. The Dutch translation will now be further validated with objective measures of GIT involvement.

References

1.    Khanna D, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.

2.    Beaton, D.E., et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000;25:3186-91.


Disclosure:

J. Meijs,

Actelion Pharmaceuticals,

2;

D. Pors,
None;

T. P. M. Vliet Vlieland,
None;

T. W. J. Huizinga,
None;

A. J. M. Schuerwegh,

Actelion Pharmaceuticals,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dutch-translation-and-validation-of-the-university-of-california-los-angeles-scleroderma-clinical-trial-consortium-gastrointestinal-tract-instrument-2-0/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology